cas 1589082-26-7|| where to buy (S)-2-(piperazin-2-yl)acetonitrile

Produktname:(S)-2-(piperazin-2-yl)acetonitrile

IUPAC Name:2-[(2S)-piperazin-2-yl]acetonitrile

Packungseinheit	Verfügbarer Vorrat	Preis($)	Menge
CM325414-1g	in stock	ȬȬ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1589082-26-7 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:1589082-26-7; Molekulare Formel:C6H11N3; Schmelzpunkt:-; SMILES-Code:N#CC[C@@H]1NCCNC1; Dichte:

: Katalognummer:CM325414; Molekulargewicht:125.18; Siedepunkt:; Mdl-Nr.:; Lagerung:

: Piperazines; Piperazine is an organic compound consisting of a six-membered ring containing two nitrogen atoms in opposite positions in the ring. The chemical formula of piperazine is C4H10N2, and it is an important pharmaceutical intermediate. Pyrimidines and piperazines are known to be the backbone of many bulk compounds and important core structures for approved drugs; studies have shown that combining a pyridine ring with a piperazine moiety within a single structural framework enhances biological activity.

: Adagrasib; Jan. 10, 2024, EC approves KRAZATI (adagrasib) as a targeted treatment option for patients with advanced non-small cell lung cancer (NSCLC) with a KRAS G12C mutation.
Adagrasib is an orally available, potent, irreversible, small molecule inhibitor of KRAS G12C mutant isoform for the treatment of solid tumours harbouring KRAS G12C oncogenic driver mutation. Adagrasib covalently binds to the mutant cysteine in KRAS G12C and locks the mutant KRAS protein in its inactive state, thereby preventing downstream signalling without affecting wild-type KRAS protein.